[Glucocorticoid treatment for early postoperative cholangiole cholestasis hyperbilirubinemia after liver transplantation].
OBJECTIVE
To study the therapeutic effect of glucocorticoid on early postoperative cholangiole cholestasis hyperbilirubinemia after liver transplantation.


METHODS
Thirteen liver transplantation recipients with serum total bilirubin above 171 micromol/L at two weeks to one month postoperatively were enrolled in this study. After exclusion of liver blood supply anomalies, bile duct complications, and acute rejection and establishment of a pathological diagnosis of cholangiole cholestasis by hepatic biopsy, hydrocortisone sodium succinate was infused. The liver functions of the patients were tested at 1 day before and 1 day and 1 week after the treatment. Hepatic biopsy was performed before and 1 week after the treatment to observe histopathological changes.


RESULTS
The serum levels of total bilirubin decreased significantly after the treatment with glucocorticoid. Pathology of the hepatic biopsy demonstrated the resolution of cholangiole cholestasis 1 week after the treatment.


CONCLUSIONS
Glucocorticoid treatment is effective for early postoperative cholangiole cholestasis hyperbilirubinemia after liver transplantation.
Lin
Jian-hua
JH
Department of Hepatobiliary Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. GDWKLJH@163.com
Cui
Zhong-lin
ZL
Zhou
Jie
J
D000328:Adult; D000368:Aged; D002780:Cholestasis, Intrahepatic / Q000150:complications*; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006932:Hyperbilirubinemia / Q000188:drug therapy* / Q000209:etiology; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000188:drug therapy*
C007133:hydrocortisone hemisuccinate; D006854:Hydrocortisone